Compare AstraZeneca plc (AZN) vs Ishares Msci Brazil ETF (EWZ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Ishares Msci Brazil ETF — how do they compare? AstraZeneca plc trades at $167.05 (market cap $253.13B), while Ishares Msci Brazil ETF trades at $36.11. The key difference: AstraZeneca plc pays a 1.92% dividend while Ishares Msci Brazil ETF pays none, and Ishares Msci Brazil ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | EWZ | |
|---|---|---|
Market Cap | $253.13B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $209.48 | $41.75 |
52-Week Low | $137.44 | $26.52 |
Enterprise Value | $279.37B | — |
Dividend Yield | 1.92% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
EWZ, the iShares MSCI Brazil ETF, trades at $35.39, down 1.5% for the day, with a bullish technical signal driven by moving averages. The ETF has gained approximately 11% year-to-date, supported by Brazil's monetary easing cycle and commodity strength. Recent news highlights its exposure to Latin America's equity rally and potential from Brazil's $10 billion Eco Invest auction aimed at sustainable technologies.
The outlook for EWZ is positive, with upside from Brazil's rate cuts and commodity markets, but risks include dependence on volatile commodity prices and potential derailment of the easing cycle. The ETF offers a discounted entry to Brazilian equities, yet payout consistency is a concern due to its concentrated holdings in firms like Petrobras and Vale.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Ishares Msci Brazil ETF
EWZ is a country-specific ETF that tracks the Brazilian equity market. It provides exposure to large and mid-sized companies in Brazil, with a heavy focus on financials and materials, including major names like Nu Holdings, Vale, and Itaú Unibanco.
Read more on EWZ →
